Press release
Severe Hypertriglyceridemia Pipeline Drugs 2024 | Arrowhead Pharmaceuticals, Ionis Pharmaceuticals, Inc., 89bio, Inc., Regeneron Pharmaceuticals, Kowa Research Institute, Inc., Mochida Pharmaceutical,
Discover the latest drugs and treatment options in the Severe Hypertriglyceridemia Pipeline. Dive into DelveInsight's comprehensive report today! @ Severe Hypertriglyceridemia Pipeline Outlook [https://www.delveinsight.com/sample-request/severe-hypertriglyceridemia-shtg-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Severe Hypertriglyceridemia Pipeline Report
* August 2024:- Ionis Pharmaceuticals- An Open-Label Extension Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Patients With Severe Hypertriglyceridemia (SHTG). This is a multi-center, open-label study of up to 700 participants with SHTG who would be rolled over from studies ISIS 678354-CS5 (NCT05079919) or ISIS 678354-CS6 (NCT05552326). Day 1 of this study may be same as the Week 53 visit of either ISIS 678354-CS5 or ISIS 678354-CS6, as applicable. Participants will receive olezarsen during the 53-week treatment period. The study will include a 31-day qualification Period, a 53-week treatment period, and a 13-week post-treatment period.
* DelveInsight's Severe Hypertriglyceridemia pipeline report depicts a robust space with 10+ active players working to develop 10+ pipeline therapies for Severe Hypertriglyceridemia treatment.
* The leading Severe Hypertriglyceridemia Companies such as Arrowhead Pharmaceuticals, Ionis Pharmaceuticals, Inc., 89bio, Inc., Regeneron Pharmaceuticals, Kowa Research Institute, Inc., Mochida Pharmaceutical, Acasti Pharma Inc., NorthSea Therapeutics, Matinas BioPharma, and others.
* Promising Severe Hypertriglyceridemia Therapies such as Olezarsen, Plozasiran Injection, and others.
Stay ahead with the most recent pipeline outlook for Severe Hypertriglyceridemia. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Severe Hypertriglyceridemia Treatment Drugs [https://www.delveinsight.com/sample-request/severe-hypertriglyceridemia-shtg-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr]
Severe Hypertriglyceridemia Emerging Drugs Profile
* ARO-APOC3: Arrowhead Pharmaceuticals
ARO-APOC3 is designed to reduce production of Apolipoprotein C-III (apoC-III), a component of triglyceride rich lipoproteins (TRLs) including VLDL and chylomicrons and is a key regulator of triglyceride metabolism. The company believes that knocking down the hepatic production of apoC-III may result in reduced VLDL synthesis and assembly, enhanced breakdown of TRLs, and better clearance of VLDL and chylomicron remnants. Currently, it is in Phase II stage of clinical trial evaluation to treat Severe Hypertriglyceridemia.
* Olezarsen: Ionis Pharmaceuticals
Olezarsen, formerly known as IONIS-APOCIII-LRx and AKCEA-APOCIII-LRx, is a ligand-conjugated (LICA) investigational antisense medicine designed to inhibit the production of apoC-III in the liver. ApoC-III is a protein that regulates triglyceride metabolism in the blood by inhibiting lipoprotein lipase that breakdown triglycerides and by preventing clearance of triglyceride-rich lipoproteins. ApoC-III is an independent risk factor for both pancreatitis and cardiovascular disease.
Explore groundbreaking therapies and clinical trials in the Severe Hypertriglyceridemia Pipeline. Access DelveInsight's detailed report now! @ New Severe Hypertriglyceridemia Drugs [https://www.delveinsight.com/sample-request/severe-hypertriglyceridemia-shtg-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr]
Severe Hypertriglyceridemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration
* Inhalation
* Inhalation/Intravenous/Oral
* Intranasal
* Intravenous
* Intravenous/ Subcutaneous
* NA
* Oral
* Oral/intranasal/subcutaneous
* Parenteral
* Subcutaneous
Severe Hypertriglyceridemia Products have been categorized under various Molecule types such as
* Antibody
* Antisense oligonucleotides
* Immunotherapy
* Monoclonal antibody
* Peptides
* Protein
* Recombinant protein
* Small molecule
* Stem Cell
* Vaccine
Unveil the future of Severe Hypertriglyceridemia Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Severe Hypertriglyceridemia Market Drivers and Barriers [https://www.delveinsight.com/sample-request/severe-hypertriglyceridemia-shtg-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Severe Hypertriglyceridemia Pipeline Report
* Coverage- Global
* Severe Hypertriglyceridemia companies- Arrowhead Pharmaceuticals, Ionis Pharmaceuticals, Inc., 89bio, Inc., Regeneron Pharmaceuticals, Kowa Research Institute, Inc., Mochida Pharmaceutical, Acasti Pharma Inc., NorthSea Therapeutics, Matinas BioPharma, and others.
* Severe Hypertriglyceridemia Therapies such as Olezarsen, Plozasiran Injection, and others.
* Severe Hypertriglyceridemia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Severe Hypertriglyceridemia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Get the latest on Severe Hypertriglyceridemia Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Severe Hypertriglyceridemia Companies, Key Products and Unmet Needs [https://www.delveinsight.com/sample-request/severe-hypertriglyceridemia-shtg-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* Severe Hypertriglyceridemia: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Severe Hypertriglyceridemia - DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Olezarsen: Ionis Pharmaceuticals
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* ARO-APOC3: Arrowhead Pharmaceuticals
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* Drug name: Company name
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug name: Company name
* Drug profiles in the detailed report.....
* Inactive Products
* Severe Hypertriglyceridemia Key Companies
* Severe Hypertriglyceridemia Key Products
* Severe Hypertriglyceridemia- Unmet Needs
* Severe Hypertriglyceridemia- Market Drivers and Barriers
* Severe Hypertriglyceridemia- Future Perspectives and Conclusion
* Severe Hypertriglyceridemia Analyst Views
* Severe Hypertriglyceridemia Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=severe-hypertriglyceridemia-pipeline-drugs-2024-arrowhead-pharmaceuticals-ionis-pharmaceuticals-inc-89bio-inc-regeneron-pharmaceuticals-kowa-research-institute-inc-mochida-pharmaceutical]
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Severe Hypertriglyceridemia Pipeline Drugs 2024 | Arrowhead Pharmaceuticals, Ionis Pharmaceuticals, Inc., 89bio, Inc., Regeneron Pharmaceuticals, Kowa Research Institute, Inc., Mochida Pharmaceutical, here
News-ID: 3609284 • Views: …
More Releases from ABNewswire
Boca Raton Moving Broker Sees Surge in Demand as Families Seek Transparent Inter …
Safe Ship Moving Services, a Boca Raton-based interstate moving broker, reports rising demand as families, businesses, and military households seek transparent pricing and reliable communication. By matching customers with vetted, licensed carriers nationwide, the company has coordinated over 40,000 moves while emphasizing upfront estimates, virtual consultations, and strict carrier screening standards.
Safe Ship Moving Services has coordinated more than 40,000 household relocations across state lines since launching operations from its Boca…
How to Create a CapCut Template in 2026: A Complete Creator's Playbook
Image: https://www.abnewswire.com/upload/2026/02/4e061e81741ac5e16f33937c9ebbf9c8.jpg
Designing your own CapCut templates is no longer just a "nice-to-have" skill. In 2026, templates are one of the fastest ways to edit consistently, protect your visual identity, and scale content production without burning out.
This in-depth guide walks you through how to build CapCut templates from the ground up, whether you are editing on mobile or desktop. You will also learn how to structure reusable workflows, avoid common mistakes,…
Marketing Strategist Katina Ndlovu Demonstrates How Google Local Services Ads Ca …
This case study examines how a service-based business generated 280 high-intent leads in two months using Google Local Services Ads by focusing on phone-driven enquiries, trust signals, and operational readiness rather than traffic volume. The campaign achieved consistent top-of-search visibility, capturing decision-ready customers and producing stable inbound demand. It highlights why aligning marketing systems with real buyer behaviour is essential for sustainable local growth.
Johannesburg, South Africa - Marketing strategy consultant…
How to Build a Red Light + Skincare Regimen for Visible Results All Year
Mito Red Light is pioneering a new category of skincare known as Light-Activated Skincare, combining red and near-infrared light therapy with topical formulations designed to respond to light exposure. The company's latest educational release outlines how to build a year-round red light skincare regimen using its MitoAURA Trademark Activate + Amplify Serum, while announcing an upcoming split-face study to evaluate the added benefits of light-activated skincare compared to light therapy…
More Releases for Severe
Severe Acne Vulgaris or Severe Recalcitrant Nodular Acne Clinical Trials, Compan …
DelveInsight's "Severe Acne Vulgaris or Severe Recalcitrant Nodular Acne Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Severe Acne Vulgaris or Severe Recalcitrant Nodular Acne, historical and forecasted epidemiology as well as the Severe Acne Vulgaris or Severe Recalcitrant Nodular Acne market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
DelveInsight's analysis highlights that several key companies are actively…
Severe Combined Immunodeficiency (SCID) Market: A Comprehensive Overview
Severe Combined Immunodeficiency (SCID) is a rare but life-threatening genetic disorder that affects the immune system, leaving individuals vulnerable to infections. It is often referred to as "bubble boy disease," due to its dramatic impact on the immune system, which fails to protect the body from pathogens. SCID can be caused by various mutations in different genes, and it leads to a complete or near-complete absence of functional T-cells and…
Severe Breathing Care Ventilator Market Size 2024 to 2031.
Market Overview and Report Coverage
The Severe Breathing Care Ventilator Market refers to the market for medical devices that help patients with severe breathing difficulties by providing assistance with their respiration. These ventilators are crucial in treating patients with conditions such as respiratory failure, chronic obstructive pulmonary disease (COPD), and acute respiratory distress syndrome (ARDS).
The future outlook for the Severe Breathing Care Ventilator Market is very promising, with a…
Severe Asthma Treatment Market - Revitalizing Quality of Life: Severe Asthma Tre …
Newark, New Castle, USA: The "Severe Asthma Treatment Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors.
Severe Asthma Treatment Market: https://www.growthplusreports.com/report/severe-asthma-treatment-market/8939
This latest report researches the industry structure,…
Severe Hypertriglyceridemia Market - Breaking Barriers in Managing Cholesterol L …
Newark, New Castle, USA: The "Severe Hypertriglyceridemia Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors.
Severe Hypertriglyceridemia Market: https://www.growthplusreports.com/report/severe-hypertriglyceridemia-market/8763
This latest report researches the industry structure, sales, revenue,…
Severe Acute Respiratory Syndrome (SARS) - Pipeline Review, H1 2017
ReportsWorldwide has announced the addition of a new report title Severe Acute Respiratory Syndrome (SARS) - Pipeline Review, H1 2017 to its growing collection of premium market research reports.
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Severe Acute Respiratory Syndrome (SARS) - Pipeline Review, H1 2017, provides an overview of the Severe Acute Respiratory Syndrome (SARS) (Infectious Disease) pipeline landscape.
Severe acute respiratory syndrome (SARS) is a serious, potentially…
